Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05437419 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis
A Phase 1 study of Rheumatoid Arthritis, sponsored by Teijin America.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 8
- Study locations
NCT05437419 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by Teijin America. The registered enrollment target is 32 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The trial reports 8 study locations across 3 states.
The verdict
NCT05437419, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by Teijin America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 8
- Study locations
Study Summary
The study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of multiple orally administered TCK-276 in both males and females with Rheumatoid Arthritis (RA).
Conditions Studied
Interventions
- DRUG TCK-276
- DRUG TCK-276 Placebo
Study Locations (8)
Florida
- St. Jude Clinical Research, LLC - Doral
- SouthCoast Research Center, Inc - Miami
- Allied Biomedical Research Institute - Miami
- San Marcus Research Clinic, Inc. - Miami Lakes
- Floridian Clinical Research, LLC - Miami Lakes
- Clinical Site Partners, LLC dba CSP Orlando - Winter Park
California
- Orange County Research Center - Tustin
Texas
- SMS Clinical Research, LLC - Mesquite
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-08-10 |
| Est. Completion | 2023-07-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05437419
The ClinicalTrials.gov registry entry for NCT05437419 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (99% lower). The listed sponsor is Teijin America, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which TCK-276 is the first listed.
NCT05437419 reports 8 study locations spanning 3 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT05437419 about?
NCT05437419 is a clinical study titled "A Study to Investigate Safety, Tolerability, and PK of Oral Doses of TCK-276 in Patients With Rheumatoid Arthritis". The study is to evaluate the safety, tolerability, and pharmacokinetic (PK) of multiple orally administered TCK-276 in both males and females with Rheumatoid Arthritis (RA).
What is the current status of trial NCT05437419?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2022-08-10. Estimated completion is 2023-07-27.
What conditions does trial NCT05437419 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT05437419?
The interventions under investigation include: TCK-276 (DRUG), TCK-276 Placebo (DRUG).
Who is sponsoring clinical trial NCT05437419?
This trial is sponsored by Teijin America, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05437419 being conducted?
This trial has 8 study locations across California, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.